Recent Updates
Recently added Catalysts
NPCE Positive Sentiment

NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference

Key Takeaway: NeuroPace, Inc. announced its participation in the Piper Sandler 35th Annual Healthcare Conference, scheduled for November 28-30 in New York. CEO Joel Becker will present on November 28, followed by one-on-one meetings with investors. The company's RNS System, aimed at treating epilepsy, is the only commercially available brain-responsive platform providing personalized treatment. This engagement highlights NeuroPace's commitment to enhancing care for patients with drug-resistant epilepsy.
Price reaction · baseline $8.7 (2023-11-20 close) · hit after-hours · clean, no other NPCE news in the window
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • NeuroPace is actively engaging with investors through its presentation.
  • The company's innovative RNS System offers hope for patients with drug-resistant epilepsy.
  • Participation in a notable healthcare conference raises the company's visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator System
Phase 2 · Epilepsy

Full Press Release Details

MOUNTAIN VIEW, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced will present at the Piper Sandler 35th Annual Healthcare Conference, taking place November 28-30 in New York, NY.
Joel Becker, NeuroPace’s Chief Executive Officer, will provide a corporate presentation on Tuesday, November 28 at 2:30pm ET, and management will participate in one-on-one meetings with investors during the conference.
The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available on the Events section of NeuroPace’s Investor website at https://investors.neuropace.com/news-and-events/events.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Frequently Asked Questions

When is NeuroPace presenting at the Piper Sandler conference?

NeuroPace will present on November 28 at 2:30 PM ET.

Who is the CEO of NeuroPace?

The CEO of NeuroPace is Joel Becker.

How can I access the NeuroPace presentation?

The presentation will be available via a live webcast.

What is the focus of NeuroPace, Inc.?

NeuroPace focuses on transforming the lives of people with epilepsy.

What is the RNS System by NeuroPace?

The RNS System is the first brain-responsive platform for treating epilepsy.

Last updated: Nov 21, 2023